- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Digital Technology: A Double-Edged Sword
Technology offers the promise of engaging patients on a level never seen before.
Technology offers the promise of engaging patients on a level never seen before. The benefits of an engaged patient start with increased compliance-a great thing for pharmaceutical companies-and extend to a more active and empowered consumer of healthcare, and ultimately to better and more affordable outcomes.
But technology is a double-edged sword. Its increasing complexity leads to increasing risk and greater scrutiny.
So what does this mean to Senior Directors and Franchise Leaders at pharmaceutical companies? In this Pharm Exec article, Scott Hansen and Geogg Melick explain why it’s vital to get that technology working right first time.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
